Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a pioneering company in the field of synthetic biology, specializing in the industrial-scale production of synthetic DNA. At the heart of its operations is a proprietary semiconductor-based DNA synthesis platform, which represents a significant advancement over traditional methods. By synthesizing DNA on a 10,000-well silicon platform instead of conventional 96-well plastic plates, Twist Bioscience achieves unprecedented levels of efficiency, scalability, and cost-effectiveness. This innovation enables the production of high-quality synthetic DNA at a faster pace and lower cost, addressing key inefficiencies in the industry.
The company's product offerings include a wide range of synthetic biology tools such as oligonucleotides, genes, pathways, chassis, and genomes. These tools are critical for applications across multiple industries, including pharmaceutical research, personalized medicine, agriculture, sustainable chemical production, and emerging fields like DNA data storage and in vivo diagnostics. Twist Bioscience's platform not only accelerates research and development but also empowers organizations to innovate in areas such as biodetection and bioengineering.
Operating primarily in the United States, Twist Bioscience serves a diverse customer base that includes biotech firms, pharmaceutical companies, academic institutions, and industrial research organizations. Its business model revolves around direct sales of synthetic DNA products and services, catering to the growing demand for advanced biological engineering solutions. By leveraging its cutting-edge technology, the company has established itself as a critical enabler in the synthetic biology ecosystem.
The broader synthetic biology industry is characterized by rapid innovation and significant growth potential, driven by advancements in genomics, bioinformatics, and sustainable technologies. Twist Bioscience's focus on high-throughput, cost-effective DNA synthesis positions it as a key player in this dynamic market. However, the company faces competition from other DNA synthesis providers, necessitating continuous investment in research and development to maintain its technological edge.
What sets Twist Bioscience apart is its commitment to overcoming traditional limitations in DNA synthesis. By utilizing silicon-based manufacturing, the company not only enhances production efficiency but also expands the possibilities for synthetic biology applications. This unique approach underscores its role as a transformative force in the industry, enabling researchers and organizations to unlock new opportunities in science and technology.
In summary, Twist Bioscience combines technological innovation with a deep understanding of synthetic biology to deliver high-quality DNA synthesis solutions. Its proprietary platform and diverse product offerings make it a vital partner for industries seeking to harness the power of engineered biology. As the demand for synthetic DNA continues to grow, Twist Bioscience remains at the forefront of enabling groundbreaking advancements across multiple sectors.
Twist Bioscience Corporation has announced the opening of its new facility in Quincy, Massachusetts, enhancing its in vivo antibody discovery capacity. This growth aligns with their strategy to accelerate antibody discovery for biopharma partners. The Twist Boston location, previously acquired in November 2021, is equipped with advanced tools, including four Berkeley Lights Beacon® Optofluidic Platforms, aimed at increasing screening capacity. The company plans to further expand its site to support future growth in biologics and diagnostics.
Twist Bioscience Corporation (NASDAQ: TWST) has partnered with Ildong Pharmaceutical to license a suite of VHH antibody libraries for immuno-oncology applications. The agreement, marking Twist's first collaboration with a South Korean company, includes an upfront payment, annual fees, and royalties on product sales. The VHH libraries, known for their small size and versatility, enable the development of novel therapies targeting various diseases. This partnership aims to enhance Ildong's pipeline and supports Twist's strategic expansion in the Asia-Pacific region.
Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold, Senior VP of Business Development for Data Storage, will present at the Fujifilm 12th Annual Global IT Executive Summit in San Diego, CA, from June 22-25, 2022. Hellmold's presentation, titled "Scaling up from Data Lakes to Data Oceans," is scheduled for June 23, 3:15-3:45 PM PT. The summit focuses on data management trends and how DNA data storage can address exponential data growth. Twist Bioscience leverages a proprietary DNA synthesis platform for various applications across industries, including healthcare and agriculture.
Twist Bioscience has launched the Twist MRD Rapid 500 Panel, priced at
This innovative solution targets up to 500 genomic regions and allows researchers to receive tailored panels in as little as five days, significantly improving the monitoring of cancer treatment responses.
The product integrates with standard NGS workflows, potentially enhancing sequencing sensitivity while aiding in disease surveillance.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust, Ph.D., and CFO Jim Thorburn will present at two upcoming investor conferences. They will speak at the William Blair Growth Stock Conference on June 9 at 1:20 p.m. CT in Chicago, and at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14 at 10:40 a.m. PT in Rancho Palos Verdes. Both presentations will be webcast live and available for replay on the company's investor relations website for 30 days.
Twist Bioscience Corporation (NASDAQ: TWST) has launched the Twist Human Methylome Panel, designed to enhance research in cancer metastasis and human development. This innovative panel covers 84.2% of CpG islands and offers significant cost savings compared to traditional methods. The panel allows researchers to identify biologically relevant methylation markers, thereby supporting advanced applications in liquid biopsy technologies. It promises a higher dynamic range for accurate detection of differentially methylated regions, facilitating better diagnostic tests and research assays.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Jim Thorburn will participate in a fireside chat at the 2022 UBS Global Healthcare Conference on May 23 at 9:15 a.m. ET in New York. The event will be webcast live, accessible via the company’s Investor Calendar. A replay will be available for 30 days after the live event. Twist Bioscience is a leader in synthetic biology, utilizing innovative DNA synthesis technology to produce synthetic DNA for various applications, including healthcare and drug discovery.
BigHat Biosciences has appointed Rob Chess to its board of directors. With extensive experience in biotech leadership, Chess aims to leverage his expertise in drug discovery to enhance BigHat's mission of developing advanced antibody therapies. He is the former CEO of Nektar Therapeutics (NASDAQ:NKTR) and currently serves as Chairman at Twist Biosciences (NASDAQ:TWST). BigHat, founded in 2019 and based in the San Francisco Bay Area, focuses on innovative therapeutic solutions using AI and has raised $25 million to date, establishing key partnerships with leading biopharma.
Twist Bioscience (NASDAQ: TWST), a leader in synthetic DNA technology, announced that Steffen Hellmold will represent the company at the 2022 Materials Research Society (MRS) Spring Meeting in Honolulu, Hawaii, from May 8-13. Hellmold will participate in the '2030 Decadal Plan for Semiconductors Panel Discussion' on May 12. This panel will explore the anticipated demand for silicon-based memory and potential solutions, including DNA data storage. Twist’s innovative platform focuses on synthesizing high-quality DNA products for various sectors including healthcare and drug discovery.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a research collaboration and exclusive option license agreement with Astellas Pharma Inc. to develop proprietary antagonist antibodies targeting a checkpoint inhibitor pathway in the tumor microenvironment. The partnership includes an upfront payment and potential milestone payments for Twist, while Astellas will handle development and commercialization. This agreement marks a significant step for Twist's Biopharma division, validating its capabilities in antibody discovery and optimization.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
What does Twist Bioscience specialize in?
How does Twist Bioscience's technology differ from traditional DNA synthesis methods?
What industries benefit from Twist Bioscience's products?
How does Twist Bioscience generate revenue?
Who are Twist Bioscience's main competitors?
What makes Twist Bioscience unique in the synthetic biology market?
What applications does Twist Bioscience's technology support?
Where does Twist Bioscience derive most of its revenue?
